12:00 AM
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tofacitinib: Phase II data

A double-blind, international Phase II trial in 194 patients with moderate to severe active UC showed that twice-daily 15 mg oral tofacitinib met the primary endpoint of improving clinical response rate from baseline to week 8 vs. placebo (78% vs. 42%, p<0.001). However, the twice-daily 0.5, 3 and 10 mg doses of tofacitinib missed the endpoint (32%, 48% and 61%, respectively; p=0.39, p=0.55 and p=0.1). The 3, 10 and 15 mg doses of tofacitinib met the secondary endpoint of improving clinical remission rates from baseline to...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >